Lastly, due to unavailability of next-generation ALK TKIs such as ceritinib and alectinib before May 2018 in China, we only reviewed the medical records of crizotinib-treated NSCLC patients with ALK-rearrangement between May 2014 and May 2018 in our institute. This evidence concerns the gene ALK and non-small cell lung carcinoma.